Want to see SNES full AI Analyst Report?
Top Page
SenesTech
(NASDAQ:SNES)
Select Model
Select Model
Rating:52Neutral
Price Target:
$1.50
▲(7.91% Upside)
Action:Reiterated
Date:08/06/26
The score is held back primarily by weak financial performance—large ongoing losses and material cash burn despite improving gross margin and revenue trends. Offsetting this, technicals show improving near-term momentum above key moving averages, and the earnings call reflected meaningful operational progress, though liquidity runway and uncertain profitability timing remain key risks. Valuation support is limited due to negative earnings and no indicated dividend yield.
Positive Factors
Gross margin expansion
Sustained and improving product economics — record Q2 gross margin (73.6%) and TTM gross margin expansion — indicate strong unit economics for the core fertility‑control bait. High gross margins provide structural leverage, enabling investment in sales and marketing while lowering the revenue threshold for profitability if operating costs stabilize.
Negative Factors
High cash burn / limited runway
Ongoing cash consumption at material levels creates a structural financing risk: with roughly nine months of runway at current burn, the company will likely need external capital unless revenue scale or margin gains accelerate. Reliance on financing can dilute equity and constrain strategic flexibility over the coming year.
Read all positive and negative factors
Positive Factors
Negative Factors
Gross margin expansion
Sustained and improving product economics — record Q2 gross margin (73.6%) and TTM gross margin expansion — indicate strong unit economics for the core fertility‑control bait. High gross margins provide structural leverage, enabling investment in sales and marketing while lowering the revenue threshold for profitability if operating costs stabilize.
Read all positive factors
SenesTech (SNES) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$7.16M
Dividend YieldN/A
Average Volume (3M)66.03K
Price to Earnings (P/E)―
Beta (1Y)1.77
Revenue Growth15.67%
EPS Growth75.35%
CountryUS
Employees24
SectorBasic Materials
Sector Strength58
IndustryChemicals - Specialty
Share Statistics
EPS (TTM)-1.37
Shares Outstanding5,303,426
10 Day Avg. Volume49,700
30 Day Avg. Volume66,031
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)7.33
Price to Sales (P/S)31.57
P/FCF Ratio-11.91
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$10.00Price Target Upside619.42% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-1.48
Revenue Forecast (FY)$2.35M
SenesTech Business Overview & Revenue Model
Company Description
SenesTech, Inc. engages in the development and commercialization of a technology for managing animal pest populations through fertility control. The company offers ContraPest, a liquid bait containing the active ingredients 4-vinylcyclohexene diep...
How the Company Makes Money
SenesTech makes money primarily by selling its rodent fertility-control products (notably its branded rat fertility-control bait) through commercial channels. Revenue is generated from product sales to distributors, pest-management companies, and ...
SenesTech Earnings Call Summary
Earnings Call Date:Aug 05, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Nov 16, 2026
Earnings Call Sentiment Positive
The call highlighted strong operational momentum driven by a successful in-house e-commerce strategy: record quarterly revenue, significant Amazon and subscription growth, record gross profit and margin expansion, and early signs of B2B traction supported by new commercial capabilities. Counterbalancing these positives are continued operating losses and elevated operating expenses, significant near-term cash usage with a ~9-month runway, dependence on sustaining e-commerce momentum, and uncertainty around the timing and scale of large B2B wins and international regulatory approvals. Overall, the results show meaningful progress on execution but the company remains early in converting that momentum into profitability.Positive Updates
Record Quarterly Revenue
Revenue reached a company record of $770,000 for Q2 FY2026, up 56% sequentially and up 23% year-over-year; first-half revenue totaled $1.26M, up 14% year-over-year.
Negative Updates
Continued Operating Losses
Net loss for the quarter was $1.8M; adjusted EBITDA loss was $1.4M (improved 15% sequentially but wider versus the prior year non-GAAP comparison), indicating the company remains unprofitable.
Read all updates
Q2-2026 Updates
Positive
Negative
Record Quarterly Revenue
Revenue reached a company record of $770,000 for Q2 FY2026, up 56% sequentially and up 23% year-over-year; first-half revenue totaled $1.26M, up 14% year-over-year.
Read all positive updates
Company Guidance
Management did not provide formal forward revenue guidance but outlined clear priorities (scale e‑commerce, grow subscriptions/retention, build B2B by vertical, launch assessment services) and said cash as of June 30 was $5.1M, which together with current run rates should fund operations for at least nine months. Key Q2 metrics cited as evidence of the plan’s traction: total revenue $770K (+56% sequential, +23% year‑over‑year), e‑commerce $511K (record; +186% seq, +206% YoY) including in‑house Amazon $349K (+473% seq; June record $148K) and non‑Amazon/shopify $155K (+31% seq); Q2 subscription/DTC revenue $104K (+89% seq, +142% YoY) with July subscription $52K (+22% vs June) and combined subscriber counts +117%; H1 revenue $1.26M (+14% YoY); product mix Evolve $662K (86% of product revenue, +27% YoY) and ContraPest $107K (+2% YoY, +43% vs Q1); gross profit $567K and record gross margin 73.6% (up 510 bps sequential, 810 bps YoY); adjusted EBITDA loss improved to $1.4M (‑15% seq); net loss improved sequentially to $1.8M; operating expenses $2.4M (including $270K severance); quarterly cash usage ~$1.7M with June burn of $298K.SenesTech Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
46
Neutral
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.37M | 2.22M | 1.86M | 1.19M | 1.02M | 576.00K |
| Gross Profit | 1.54M | 1.39M | 1.00M | 539.00K | 464.00K | 220.00K |
| EBITDA | -6.89M | -6.23M | -6.01M | -7.57M | -9.51M | -7.95M |
| Net Income | -7.00M | -6.38M | -6.18M | -7.71M | -9.70M | -8.27M |
Balance Sheet | ||||||
| Total Assets | 9.42M | 12.84M | 3.28M | 7.29M | 6.78M | 11.50M |
| Cash, Cash Equivalents and Short-Term Investments | 5.08M | 8.57M | 1.31M | 5.39M | 4.78M | 9.33M |
| Total Debt | 2.58M | 2.68M | 262.00K | 406.00K | 359.00K | 555.00K |
| Total Liabilities | 3.37M | 3.27M | 767.00K | 942.00K | 1.50M | 1.47M |
| Stockholders Equity | 6.05M | 9.57M | 2.51M | 6.35M | 5.28M | 10.04M |
Cash Flow | ||||||
| Free Cash Flow | -6.74M | -5.89M | -6.12M | -7.71M | -8.75M | -7.88M |
| Operating Cash Flow | -6.68M | -5.75M | -6.03M | -7.57M | -8.58M | -7.78M |
| Investing Cash Flow | -1.02M | -1.10M | -56.00K | -149.00K | -170.00K | -99.00K |
| Financing Cash Flow | 5.55M | 13.12M | 2.00M | 8.34M | 4.20M | 13.56M |
SenesTech Technical Analysis
Negative
1.39
Price Trends
1.51
Negative
1.58
Negative
2.03
Negative
Market Momentum
-0.02
Negative
41.97
Neutral
35.71
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SNES, the sentiment is Negative. The current price of 1.39 is below the 20-day moving average (MA) of 1.40, below the 50-day MA of 1.51, and below the 200-day MA of 2.03, indicating a bearish trend. The MACD of -0.02 indicates Negative momentum. The RSI at 41.97 is Neutral, neither overbought nor oversold. The STOCH value of 35.71 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SNES.
SenesTech Risk Analysis
SenesTech disclosed 31 risk factors in its most recent earnings report. SenesTech reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
SenesTech Peers Comparison
UnderperformOutperform
Sector (61)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | $5.38B | 32.73 | 12.79% | 0.59% | 10.14% | 16.56% | |
76 Outperform | $78.14B | 37.02 | 21.41% | 1.06% | 7.11% | -0.48% | |
62 Neutral | $1.46B | -534.50 | -0.22% | 2.73% | 7.63% | -104.57% | |
62 Neutral | $8.95B | 49.96 | 6.57% | 0.85% | 26.61% | -25.95% | |
61 Neutral | $10.43B | 7.12 | -0.05% | 2.87% | 2.86% | -36.73% | |
52 Neutral | $7.16M | -0.71 | -76.20% | ― | 15.67% | 75.35% | |
51 Neutral | $4.99B | -13.91 | -30.38% | ― | 24.25% | -515.23% |
* Basic Materials Sector Average
SNES
SenesTech
1.29
-3.08
-70.48%
BCPC
Balchem
179.43
21.52
13.63%
ECL
Ecolab
285.17
14.56
5.38%
SCL
Stepan Company
65.15
18.06
38.35%
ESI
Element Solutions
37.88
14.35
60.96%
PRM
Perimeter Solutions
35.26
17.45
97.98%
SenesTech Corporate Events
Executive/Board ChangesShareholder Meetings
SenesTech Shareholders Approve Directors, Compensation and Equity Plan
Positive
Jun 10, 2026
On June 9, 2026, SenesTech, Inc. held its 2026 annual meeting of stockholders, at which shareholders elected Jake S. Leach and Joshua M. Moss as Class I directors to serve three-year terms ending with the 2029 annual meeting. Investors also approv...
Business Operations and StrategyExecutive/Board Changes
SenesTech Appoints Michael Edell as New CEO and President
Positive
May 7, 2026
On May 6, 2026, SenesTech, Inc. appointed former Interim Chief Operating Officer Michael Edell as its new president and chief executive officer, succeeding Joel L. Fruendt, and simultaneously named him to the board as a Class III director with a t...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.